Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 14;14(4):953. doi: 10.3390/cancers14040953

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Currently approved indications of PARP inhibitors according to the Food and Drug Administration. * Olaparib in combination with bevacizumab; ** This indication has not been approved yet, but has been granted an accelerated review process by the Food and Drug Administration on 30 November 2021. Figure Legend: 1L first line therapy; 2L second line therapy; BRCAm: BRCA mutated (germline or somatic); gBRCAm: germline BRCA mutated; HRD homologous recombination deficiency; HRRm: homologous recombination repair mutated.